Breaking News Instant updates and real-time market news.

MRK

Merck

$62.77

0.11 (0.18%)

15:34
10/09/16
10/09
15:34
10/09/16
15:34

Merck reports long-term data from final KEYNOTE-002 analysis

Merck announced findings from the final overall survival analysis from the KEYNOTE-002 study investigating the use of Keytruda compared to investigator-choice chemotherapy with a crossover to Keytruda design, in patients with ipilimumab-refractory advanced melanoma. The results presented at the ESMO 2016 Congress include follow-up of up to 35 months for the study's co-primary endpoints of OS and progression-free survival. Data showed prolonged OS with Keytruda 2 mg/kg and 10 mg/kg, with a median OS of 13.4 months and 14.7 months and a two-year OS rate of 35.9 percent and 38.2 percent, respectively, compared to a median OS of 11.0 months and a two-year OS rate of 29.7 percent with chemotherapy. While improvements in OS between Keytruda 2 mg/kg or 10 mg/kg and chemotherapy did not meet the protocol-specified significance threshold, longer follow-up continued to show a clinically meaningful improvement in PFS, the study's co-primary endpoint, with PFS of up to 31 months in patients treated with Keytruda. Median PFS was approximately three months for each of the patient groups -- 2.8-3.8 months with Keytruda 2 mg/kg; 2.8-5.2 months with Keytruda 10 mg/kg; and 2.6-2.8 months with chemotherapy. The two-year PFS rate was 16.0 percent and 21.9 percent with Keytruda compared to 0.6 percent of patients treated with chemotherapy. ORR was 22.2 percent and 27.6 percent with Keytruda compared to 4.5 percent with chemotherapy. At the time of analysis, 50 percent and 58 percent of patients who responded to Keytruda were alive with no subsequent progression or anti-tumor therapy, compared to 12 percent of patients who responded to chemotherapy. With longer follow-up, adverse events have remained consistent with previously reported safety data.

  • 25

    Oct

  • 06

    Nov

MRK Merck
$62.77

0.11 (0.18%)

09/21/16
FBCO
09/21/16
UPGRADE
Target $41
FBCO
Outperform
Clovis upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Kennen MacKay upgraded Clovis Oncology (CLVS) to Outperform and raised his price target for the shares to $41 from $19. Clovis closed yesterday up 13%, or $3.92, to $34.83. The potential for a takeover "outweighs concerns surrounding patent life, limited experience in platinum resistant/refractory patients, and PARPi competition," MacKay tells investors in a research note. Clovis could be worth $35-$41 per share in a buyout on operational synergies, and $52-$55 per share with leveraged tax benefits, MacKay estimates. He points out that Eli Lilly (Lill)y, Merck (MRK), Japan's Takeda and others have expressed interest in acquiring U.S. oncology companies.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
10/07/16
LEER
10/07/16
NO CHANGE
LEER
Outperform
Incyte Epacadostat Phase 1 Melanoma data maturing well, says Leerink
Leerink analyst Michael Schmidt says the data from ECHO-202 Phase 1 study evaluating the combination of Incyte's (INCY) IDO1 inhibitor epacadostat with Merck's (MRK) Keytruda confirms the previously published results and appears to be maturing well. The analyst reiterates an Outperform rating on Incyte's shares, saying Jakafi remains a compelling long-term growth driver for the company, expectations for baricitinib are still moderate, and its maturing oncology pipeline of 14 molecules including epacadostat represents a long-term value driver.

TODAY'S FREE FLY STORIES

14:20
09/26/17
09/26
14:20
09/26/17
14:20
Conference/Events
FBN Securities strategist to hold an analyst/industry conference call »

Chief Market Strategist…

BLK

BlackRock

$434.46

-3.17 (-0.72%)

14:20
09/26/17
09/26
14:20
09/26/17
14:20
Options
Far upside call buyer in Blackrock opens a notable new position »

Far upside call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 22

    Oct

SYT

Syngenta

$92.07

-0.01 (-0.01%)

14:18
09/26/17
09/26
14:18
09/26/17
14:18
Hot Stocks
Syngenta reports pending settlement to resolve corn litigation »

Plaintiffs and defendants…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
09/26/17
09/26
14:17
09/26/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
09/26/17
09/26
14:16
09/26/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DAL

Delta Air Lines

$48.42

0.1 (0.21%)

14:10
09/26/17
09/26
14:10
09/26/17
14:10
Options
Delta calls outpace puts 10:1 as a bullish spread is opened »

Delta calls outpace puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$65.78

1.24 (1.92%)

, UNH

UnitedHealth

$192.38

0.63 (0.33%)

14:09
09/26/17
09/26
14:09
09/26/17
14:09
Periodicals
GOP agrees not to vote on healthcare bill, CNN reports »

Senate Majority Leader…

MOH

Molina Healthcare

$65.78

1.24 (1.92%)

UNH

UnitedHealth

$192.38

0.63 (0.33%)

CNC

Centene

$92.15

1.82 (2.01%)

WCG

WellCare

$165.88

1.7305 (1.05%)

CI

Cigna

$183.10

1.66 (0.91%)

ANTM

Anthem

$183.18

1.68 (0.93%)

HNT

Health Net

HUM

Humana

$239.83

2.62 (1.10%)

AET

Aetna

$153.66

1.6785 (1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 26

    Sep

  • 27

    Sep

  • 04

    Oct

  • 17

    Oct

  • 24

    Oct

  • 08

    Nov

FL

Foot Locker

$34.77

0.11 (0.32%)

14:05
09/26/17
09/26
14:05
09/26/17
14:05
Options
Foot Locker call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AXP

American Express

$88.48

0.27 (0.31%)

13:58
09/26/17
09/26
13:58
09/26/17
13:58
Hot Stocks
American Express raises quarterly dividend 9% to 35c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

  • 18

    Oct

  • 22

    Oct

FIT

Fitbit

$6.49

0.045 (0.70%)

13:57
09/26/17
09/26
13:57
09/26/17
13:57
Hot Stocks
Fitbit to participate in FDA software pilot program »

Fitbit announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

FB

Facebook

$162.87

-7.67 (-4.50%)

, WMT

Wal-Mart

$79.48

0.33 (0.42%)

13:51
09/26/17
09/26
13:51
09/26/17
13:51
Hot Stocks
Wal-Mart to roll out Workplace by Facebook »

Julien Codorniou, the VP…

FB

Facebook

$162.87

-7.67 (-4.50%)

WMT

Wal-Mart

$79.48

0.33 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 08

    Oct

  • 10

    Oct

  • 22

    Oct

  • 16

    Nov

  • 21

    Nov

  • 20

    Feb

PTEN

Patterson-UTI

$20.47

0.94 (4.81%)

13:50
09/26/17
09/26
13:50
09/26/17
13:50
Options
Put buyers active in Patterson Energy »

Put buyers active in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$162.87

-7.67 (-4.50%)

, SLF

Sun Life Financial

$39.46

0.19 (0.48%)

13:49
09/26/17
09/26
13:49
09/26/17
13:49
Hot Stocks
Sun Life Financial announces launch of Workplace by Facebook »

Sun Life Financial (SLF)…

FB

Facebook

$162.87

-7.67 (-4.50%)

SLF

Sun Life Financial

$39.46

0.19 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

  • 03

    Oct

  • 08

    Oct

  • 22

    Oct

ELF

e.l.f. Beauty

$19.68

-0.025 (-0.13%)

, WBA

Walgreens Boots Alliance

$78.96

0.55 (0.70%)

13:46
09/26/17
09/26
13:46
09/26/17
13:46
Recommendations
e.l.f. Beauty, Walgreens Boots Alliance analyst commentary  »

e.l.f. Beauty products…

ELF

e.l.f. Beauty

$19.68

-0.025 (-0.13%)

WBA

Walgreens Boots Alliance

$78.96

0.55 (0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

13:45
09/26/17
09/26
13:45
09/26/17
13:45
General news
Fed funds futures slid lower on the heels of Yellen's comments »

Fed funds futures slid…

SRCI

SRC Energy

$9.18

0.36 (4.08%)

13:40
09/26/17
09/26
13:40
09/26/17
13:40
Options
Call writer opens a notable new position in SRC Energy as shares outperform »

Call writer opens a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 16

    May

HMNY

Helios and Matheson

$8.30

1.33 (19.08%)

13:40
09/26/17
09/26
13:40
09/26/17
13:40
Periodicals
Helios and Matheson mentioned cautiously by TheStreetSweeper 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDP

Meredith

$54.05

-0.35 (-0.64%)

13:31
09/26/17
09/26
13:31
09/26/17
13:31
Hot Stocks
Meredith names Alysia Borsa chief marketing and data officer »

Meredith Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BWP

Boardwalk Pipeline

$14.95

0.1734 (1.17%)

13:30
09/26/17
09/26
13:30
09/26/17
13:30
Options
In the money call buying continues in Boardwalk Pipeline »

In the money call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
09/26/17
09/26
13:30
09/26/17
13:30
General news
More from Yellen: not much new in her Q&A, reiterating the two sided risks »

More from Yellen: not…

NKE

Nike

13:29
09/26/17
09/26
13:29
09/26/17
13:29
Periodicals
Nike: Code left company over 3 years ago, no longer an employee, Bloomberg says »

Merl Code, the former…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 03

    Oct

  • 04

    Oct

  • 10

    Oct

13:20
09/26/17
09/26
13:20
09/26/17
13:20
General news
Treasury Action: yields steadied below highs »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

13:17
09/26/17
09/26
13:17
09/26/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

13:16
09/26/17
09/26
13:16
09/26/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TGT

Target

$58.49

-0.06 (-0.10%)

13:15
09/26/17
09/26
13:15
09/26/17
13:15
Conference/Events
Target management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.